BTG International, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.7M
Doctors Paid
2,436
Transactions
5,589
2024 Total
$1.2M
Payment Breakdown by Category
Research$4.4M (50.1%)
Consulting$2.1M (24.5%)
Travel$401,914 (4.6%)
Food & Beverage$187,220 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.4M | 95 | 50.1% |
| Consulting Fee | $2.1M | 248 | 24.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 366 | 12.1% |
| Travel and Lodging | $401,914 | 1,272 | 4.6% |
| Education | $219,619 | 305 | 2.5% |
| Food and Beverage | $187,220 | 3,212 | 2.1% |
| Grant | $133,600 | 27 | 1.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $133,593 | 19 | 1.5% |
| Space rental or facility fees (teaching hospital only) | $57,150 | 41 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $21,268 | 4 | 0.2% |
Payments by Type
Research
$4.4M
95 transactions
General
$4.3M
5,494 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Voraxaze Rescue Use Data | $624,792 | 0 | 6 |
| Single system double blinded trial to evaluate the effect of pre-operative treatment with digiFab to prevent post-operative actute kidney injury (AKI) in patients at high risk for AKI ungergoing cardiac graft surgery | $436,693 | 0 | 9 |
| CROFAB | $354,996 | 0 | 13 |
| Characteristics of Patients Presenting with Digoxin Toxicity and Outcomes of Patients Treated with the Digoxin Immune Fab | $304,293 | 0 | 6 |
| VORAXAZE | $273,768 | 0 | 3 |
| DIGIFAB | $209,707 | 0 | 7 |
| Effects of Digifab on renal function perioperatively | $198,193 | 0 | 3 |
| An Open-Label, Multi-Institutional Phase 0 Study to Assess the Use of Glucarpidase in Patients with Osteosarcoma Receiving High-Dose Methotrexate | $194,835 | 0 | 2 |
| Pilot Study of glucarpidase in Patients with Central Nervous System Lymphoma | $165,714 | 0 | 2 |
| Preop DigiFab in CABG to reduce ouabain levels and prevent AKI | $146,288 | 0 | 1 |
| LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | $126,058 | 0 | 2 |
| Gerardo IIS #2 | $124,000 | 0 | 2 |
| A Pilot Study of Voraxaze glucarpidase in Patietns with Central Nervous System Lymphoma | $123,114 | 0 | 3 |
| Utilization of Digoxin Immune Fab for Serious and Life-Threatening Digoxin Toxicity | $110,675 | 0 | 4 |
| An Open-Label Pilot Study to Assess the Use of Glucarpidase in Patients with Osteosarcoma Receiving High-Dose Methotrexate | $106,285 | 0 | 2 |
| Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI | $102,860 | 0 | 5 |
| An Open-Label, Multi-Institutional Pilot Study to Assess the Use of Glucarpidase in Patients with Osteosarcoma Receiving High-Dose Methotrexate | $101,272 | 0 | 1 |
| Voraxaze Planned Use Research | $98,280 | 0 | 6 |
| Prediction, Early Detection, and Treatment of Methotrexate-associated Acute Kidney Injury | $89,100 | 0 | 1 |
| Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma | $82,738 | 0 | 4 |
| Anti-tumor study of Glucarpidase with MTHFD2 inhibitor against blood cancer xenograft | $79,999 | 0 | 2 |
| An examination of coagulation and inflammatory response of healthy donor whole blood to three North American snake venoms | $64,557 | 0 | 1 |
| Retrospective review of the response to continuous Antivenom (Crofab) in patients of rattlesnake envenoming | $44,550 | 0 | 1 |
| DigiFab CABG-AKI | $43,500 | 0 | 1 |
| Combination Study of Voraxaze with methylene terahydrofolate dehydrogenase 2 inhibition | $37,408 | 0 | 1 |
| UMB - DigiFab Preclinical (Oubain assay) | $28,777 | 0 | 1 |
| Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation | $25,000 | 1 | 1 |
| Retrospective Review of High Dose Methotrexate Regimen in CNS Lymphoma Treatment | $22,793 | 0 | 1 |
| Rechallenge with Methotrexate after Administration of Glucarpidase for Methotrexate-Associated Acute Kidney Injury | $21,157 | 0 | 1 |
| Investigation of the Pathogenesis of Thrombocytopenia in Rattlesnake Envenomation via Analyses of von Willebrand Factor Multimers and ADAMTS13 Activity | $20,981 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 10
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| James Armitage, Md, MD | Hematology & Oncology | Omaha, NE | $1,068 | $0 |
| Gilles Salles | Hematology & Oncology | New York, NY | $1,068 | $0 |
| Paolo Strati, M.d, M.D | Internal Medicine | Houston, TX | $1,068 | $0 |
| Marc Hoffmann, Md, MD | Hematology & Oncology | Overland Park, KS | $1,068 | $0 |
| Julie Vose, Md, MD | Hematology & Oncology | Omaha, NE | $1,068 | $0 |
| Dr. Nitin Jain, Md, MD | Internal Medicine | Houston, TX | $1,068 | $0 |
| Dr. Faisal Cheema, M.d, M.D | Hematology & Oncology | Shreveport, LA | $1,068 | $0 |
| Dr. Kevin-Sean Mcgann, D.o, D.O | Emergency Medicine | Horsham, PA | $1,059 | $0 |
| Dr. Stephen Harding, M.d, M.D | Medical Toxicology | Houston, TX | $1,047 | $0 |
| Peter Adamson, M.d, M.D | Pediatrics | Philadelphia, PA | $1,040 | $0 |
| Dr. Carl Caroe, Md, MD | Emergency Medicine | Athens, TX | $1,033 | $0 |
| Michael Greenberg, Md, MD | Emergency Medicine | Philadelphia, PA | $1,032 | $0 |
| Dr. Jordan Larsen, Do, DO | Pediatric Emergency Medicine | Oklahoma City, OK | $1,030 | $0 |
| Dr. Stephen Mitchell, D.o, D.O | Emergency Medicine | Clearwater, FL | $1,027 | $0 |
| Dr. Alex Ho, M.d, M.D | Emergency Medicine | Tallahassee, FL | $1,024 | $0 |
| Dr. Matthew Sisko, Md, MD | Emergency Medicine | Deland, FL | $1,002 | $0 |
| Denise Cinciripini, M.d, M.D | Internal Medicine | Richland, WA | $1,001 | $0 |
| Lindsey Vollono, Pa-C, PA-C | Medical | Charleston, SC | $1,000 | $0 |
| Mrs. Katherine Alexander, Cnp, CNP | Acute Care | Columbus, OH | $1,000 | $0 |
| Susan Watson, Do, DO | Emergency Medicine | Steamboat Springs, CO | $997.41 | $0 |
| Jennifer Foster, Md, MD | Pediatric Hematology-Oncology | Houston, TX | $995.42 | $0 |
| Dr. Gordon Aalund, Md, MD | Emergency Medicine | Dallas, TX | $986.83 | $0 |
| Dr. Dwayne Miller, M.d, M.D | Family Medicine | Comanche, TX | $979.60 | $0 |
| Dr. Stephen Dickey, D.o, D.O | Family Medicine | Comanche, TX | $979.60 | $0 |
| Nupur Mittal, M.d, M.D | Pediatrics | Chicago, IL | $976.42 | $0 |
Ad
Top Products
- VORAXAZE $3.6M
- CROFAB $2.4M
Associated Products (8)
- VORAXAZE $3.7M
- CROFAB $2.4M
- DIGIFAB $1.6M
- CroFab $354,568
- CYANOKIT $164,302
- VISTOGARD-4 $25,210
- DIGIFab $24,539
- VISTOGARD-20 $17,990
Payment Categories
- Food & Beverage $187,220
- Consulting $2.1M
- Travel & Lodging $401,914
- Research $4.4M
About BTG International, Inc.
BTG International, Inc. has made $8.7M in payments to 2,436 healthcare providers, recorded across 5,589 transactions in the CMS Open Payments database. In 2024, the company paid $1.2M. The top product by payment volume is VORAXAZE ($3.6M).
Payments were distributed across 114 medical specialties. The top specialty by payment amount is Emergency Medicine ($846,884 to 633 doctors).
Payment categories include: Food & Beverage ($187,220), Consulting ($2.1M), Research ($4.4M), Travel & Lodging ($401,914).
BTG International, Inc. is associated with 8 products in the CMS Open Payments database, including VORAXAZE, CROFAB, and DIGIFAB.